Medpace (NASDAQ:MEDP) CEO Sells $6,749,952.00 in Stock

Key Points

• CEO August Troendle sold 10,880 Medpace shares at an average price of $620.40, generating $6.75 million. The sale reduced his direct ownership by 2.11% to 504,273 shares.
• Medpace shares recently traded at $624.20, up 1.9%, while the company reported quarterly revenue growth of 17.2% and earnings of $4.25 per share, beating analyst expectations.
• Analysts maintain a consensus “Hold” rating with an average price target of $595.20; institutional investors own approximately 78% of the company’s stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 10,880 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $620.40, for a total value of $6,749,952.00. Following the transaction, the chief executive officer directly owned 504,273 shares in the company, valued at $312,850,969.20. This trade represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Trading Up 1.9%

NASDAQ:MEDP traded up $11.87 during mid-day trading on Monday, reaching $624.20. 184,242 shares of the stock were exchanged, compared to its average volume of 333,585. The firm has a market capitalization of $17.42 billion, a PE ratio of 36.59, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The business has a fifty day moving average price of $585.86 and a 200 day moving average price of $510.89.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in MEDP. Schulhoff & Co. Inc. grew its stake in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Balefire LLC boosted its holdings in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after buying an additional 26 shares during the period. Root Financial Partners LLC grew its stake in shares of Medpace by 34.1% in the first quarter. Root Financial Partners LLC now owns 122 shares of the company's stock valued at $59,000 after buying an additional 31 shares in the last quarter. GAMMA Investing LLC boosted its stake in Medpace by 2.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock valued at $613,000 after purchasing an additional 32 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Medpace by 0.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company's stock worth $3,718,000 after acquiring an additional 40 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. TD Cowen raised their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a report on Friday, July 24th. Mizuho raised their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a report on Friday, July 24th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.